Rare diseases
Investigational molecules
Locations
Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer
BelgiumPhase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC
AustriaStudy of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer
FranceStudy on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer
BelgiumStudy comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression
BelgiumStudy of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer
FranceA study of MK-1084 and pembrolizumab for patients with resected KRAS G12C-mutant non-small cell lung cancer
FranceRinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer
CzechiaPhase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)
FranceStudy of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion
BelgiumPhase 2 Study of PF-08634404 with Carboplatin and Etoposide in Adults with Untreated Small Cell Lung Cancer
FranceStudy of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
